344 results about "Tumour metastasis" patented technology

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

A method is provided for assessing allelic losses on specific chromosomal regions in melanoma patents. The method relies on the evidence that free DNA may be released in the plasma/serum of cancer patients allowing the detection of DNA with LOH in the plasma/serum of cancer patients by analysis for microsatellite markers. The amount of and specific allelic loss allows a prognosis to be made regarding tumor diagnosis and progression, tumor metastasis, tumor recurrence, and mortality.

Compounds and methods for the diagnosis and treatment of tumors, including breast and prostate tumors and metastases thereof using radiolabelled peptides that bind to GRP receptors. The peptides are Bombesin analogs wherein the first and optionally the third amino acid are modified.

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an anti-cancer agent and an IGF1R inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The IGF1R inhibitor is represented by Formula I:

wherein X₁, X₂, X₃, X₄, X₅, X₆, X₇, R¹, and Q¹ are defined herein.

Methods and devices for the regulation of matrix metalloproteinase gene expression in cartilage cells via the application of fields generated by specific and selective electric and electromagnetic signals in the treatment of diseased or injured articular cartilage. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased cartilage tissue that include generating specific and selective electric and electromagnetic signals that generate fields optimized for reduction of matrix metalloproteinase gene expression and exposing cartilage tissue to the fields generated by specific and selective signals so as to regulate matrix metalloproteinase gene expression in such cartilage tissue. The resulting methods and devices are useful for the targeted treatment of osteoarthritis, rheumatoid arthritis, cartilage injury, cartilage defects, and tumor metastasis.

There is provided a panel of biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-β3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1α), or tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-β3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1α, or TNC may be indicators of high metastatic potential. There is also provided a method of determining risk of tumour metastasis using the aforementioned biomarkers is also provided. The biomarkers may be used in diagnosis, prognosis, treatment selection, or to test putative therapeutics. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.

The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.

The invention discloses an acyl-tetrahydro-beta-carboline micro-molecular organic compound shown as a structural formula (I) or a hydrate thereof or pharmaceutically acceptable salts, application of a compound containing the acyl-tetrahydro-beta-carboline micro-molecular organic compound provided by the invention or a medical composition thereof to the preparation of medicaments for treating various diseases such as cancer, tumor metastasis and the like, and a preparation method of the acyl-tetrahydro-beta-carboline micro-molecular organic compound provided by the invention and derivatives thereof.

The invention discloses an in vitro model simulating human tumor metastasis. Cells in the model have a tumor high metastasis character. The model is constructed by building of a micro spherical hydrogel support frame by tumor high metastasis cells, building of a tumor cell in vitro metastasis model and identifying of the constructed tumor cell in vitro metastasis model. The model can grow in a three-dimensional culturing cell in a clustering mode, and tumor cell biological behaviors in metastasis can be detected. The model has important value in studying of a clinical tumor metastasis mechanism and controlling of screening of metastasis medicine and can be taken as a technical platform for manufacturing anti-tumor metastasis gene vaccines and building screening of anti-tumor metastasis medicine.

Provided are a medicine carrier, a micelle, an anti-tumor and anti-tumor cell metastasis pharmaceutical preparation, and a preparation method and use thereof. The medicine carrier and the micelle include a) a hydrophilic part and b) a hydrophobic part, wherein the hydrophilic part includes hydrophilic heparin compounds; and the hydrophobic part includes hydrophobic vitamin E compounds. The hydrophilic heparin compounds are connected with the hydrophobic vitamin E compounds in a specific mode. The medicine carrier and the micelle not only have an effect of anti-tumor metastasis, but also can achieve excellent effects of inhibiting tumor and tumor metastasis simultaneously by further coating anti-cancer drugs. In addition, the medicine carrier and the micelle are high in stability, and the preparation method is simple and convenient and facilitates industrial production.

The invention discloses an antibody coupled mesoporous silica/mifepristone nanometer preparation and a preparing method and application thereof. The preparation is prepared from mesoporous silica nanoparticles (MSN), mifepristone (MIF) and epithelial cell adhesion molecule antibodies (anti-EpCAM, aE), MIF is carried by MSN, and the surface of the MSN is covalently modified by aE. The ntibody coupled mesoporous silica/mifepristone nanometer preparation can recognize in a targeting mode, restrain activity of circular tumor cells (CTCs), restrain adhesion between the CTCs and endangium, disturb a tumor metastasis process and remarkably restrain tumor metastasis.

The invention relates to the field of diagnosis and treatment of tumors, in particular to a polypeptide in plasma, which has an amino acid sequence as shown in SEQ ID No.1, wherein the polypeptide can be used as a tumor marker used in a method and a kit for diagnosing the generation and the metastasis of the tumors. The invention also relates to a method and a medicament for treating tumors and metastasis of tumors.

The invention provides a new reproducible transgenic mouse model for the study of tumor metastasis. In particular, the invention concerns the study of tumor metastasis in a NOD/SCID/γ_c^null transgenic mouse model.

CD44, the receptor for hyaluronic acid, has complex functions in cellular physiology, cell migration and tumour metastasis. The inventors have previously found that human CD44 receptor overexpression in mouse fibrosarcoma cells inhibits subcutaneous tumour growth in mice [Kogerman et al., Oncogene 1997; 15:1407-16; Kogerman et al., Clin Exp Metastasis 1998; 16:83-93]. Here it is demonstrated that a tumour growth inhibitory effect of CD44 is caused by block of angiogenesis. Furthermore, the inventors have found that soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in cLick and mouse and thereby inhibits human tumour growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumours using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues is presented.

Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

The invention provides a functional red blood cell targeting circulating tumor cells (CTCs) and belongs to the technical field of red blood cell modifying and circulating tumor cell catching. A functional molecule is embedded in a cytomembrane of the functional red blood cell; one end of the functional molecule is used as an embedded end and used for being embedded in the red cell membrane; the other end of the functional molecule is used as a targeting end, the targeting end is used as a CTCs targeting antibody or folic acid and can specifically recognize and be combined with CTCs surface biomarkers; and the embedded end of the functional molecule is connected with the targeting end of the functional molecule through polyethylene glycol (PEG) to form the functional molecule with an "embedded end-PEG-targeting end" structure. The functional red blood cell can recognize, catch or inhibit the CTCs, is used for specific recognition and catching research for microscale CTCs of blood samples of clinic patients in vitro and adjusting and controlling activity of caught CTCs, and therefore the application prospect is developed on forecast and precaution of tumor metastasis.